Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2

Roberta Giuliani, Maria Bastaki*, Daniela Coltrini and Marco Presta‡

Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, 25123 Brescia, Italy

*Present address: Department of Cell Biology and Anatomy, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
‡Author for correspondence (E-mail: presta@med.unibs.it)

Accepted 20 May; published on WWW 7 July 1999

Summary

Downstream signaling triggered by the binding of fibroblast growth factor-2 (FGF2) to its tyrosine-kinase receptors involves the activation of mitogen-activated protein kinase kinase (MEK) with consequent phosphorylation of extracellular signal-regulated kinases (ERKs). Here we demonstrate that FGF2 induces ERK1/2 activation in bovine aortic endothelial (BAE) cells and that the continuous presence of the growth factor is required for sustained ERK1/2 phosphorylation. This is prevented by the MEK inhibitors PD 098059 and U0126, which also inhibit FGF2-mediated upregulation of urokinase-type plasminogen activator (uPA) and in vitro formation of capillary-like structures in three-dimensional type I collagen gel.

Various FGF2 mutants originated by deletion or substitution of basic amino acid residues in the amino terminus or in the carboxyl terminus of FGF2 retained the capacity to induce a long-lasting activation of ERK1/2 in BAE cells. Among them, K128Q/R129Q-FGF2 was also able to stimulate uPA production and morphogenesis whereas R129Q/K134Q-FGF2 caused uPA upregulation only. In contrast, K27,30Q/R31Q-FGF2, K128Q/K138Q-FGF2 and R118,129Q/K119,128Q-FGF2 exerted a significant uPA-inducing and morphogenic activity in an ERK1/2-dependent manner only in the presence of heparin. Furthermore, no uPA upregulation and morphogenesis was observed in BAE cells treated with the deletion mutant Δ27-32-FGF2 even in the presence of soluble heparin. Thus, mutational analysis of FGF2 dissociates the capacity of the growth factor to induce a persistent activation of ERK1/2 from its ability to stimulate uPA upregulation and/or in vitro angiogenesis.

In conclusion, the data indicate that ERK1/2 phosphorylation is a key step in the signal transduction pathway switched on by FGF2 in endothelial cells. Nevertheless, a sustained ERK1/2 activation is not sufficient to trigger uPA upregulation and morphogenesis. FGF2 mutants may represent useful tools to dissect the signal transduction pathway(s) mediating the complex response elicited by an angiogenic stimulus in endothelial cells.

Key words: Angiogenesis, Endothelium, ERK, FGF, Signaling, Urokinase

Introduction

Basic fibroblast growth factor (FGF2) belongs to the family of the heparin-binding growth factors (Basilico and Moscatelli, 1992). The single copy human FGF2 gene encodes multiple FGF2 isoforms with Mr ranging from 24,000 to 18,000 (Florkiewicz and Sommer, 1989). FGF2 isoforms are angiogenic in vivo and induce cell proliferation, protease production and chemotaxis in endothelial cells in vitro (Gualandris et al., 1994). FGF2 stimulates endothelial cells to form capillary-like structures in collagen gels (Montesano et al., 1986) and to invade the amniotic membrane in vitro (Mignatti et al., 1989). Also, the phenotype induced by FGF2 in endothelial cell cultures includes modulation of integrin expression (Klein et al., 1993), gap-junctional intercellular communication (Pepper and Meda, 1992) and urokinase receptor upregulation (Mignatti et al., 1991). FGF2 exerts its activity on target cells by interacting with specific tyrosine-kinase receptors (FGFRs) and heparan sulfate proteoglycans (HSPGs) of the cell surface (Johnson and Williams, 1993).

Following ligand binding, tyrosine-kinase receptors dimerize and undergo autophosphorylation. Phosphorylated tyrosines serve as docking sites for downstream signal transduction molecules containing either Src-homology 2 or phosphotyrosine-binding domains (Pawson, 1995). Thus, the capacity of growth factors to exert an array of biological responses on the same cell type is thought to reflect the...
capacity of different docking transducer proteins to associate with the activated receptor, leading to the switch of multiple intracellular signals (Pawson, 1995). At present, the intracellular signals mediating the complex response of endothelial cells to angiogenic FGF2 remain largely unknown.

Ligand-binding to FGF/R1 induces the phosphorylation of extracellular signal-regulated kinases (ERKs) by ERK kinase (MEK) (Mohammadi et al., 1996). Accordingly, ERK activation is required for cell growth induced by FGF2 in fibroblasts and myoblasts (Pages et al., 1993; Milasinovic et al., 1996), uPA gene upregulation in 3T3 fibroblasts (Besser et al., 1995), and suppression of tumor necrosis factor α-mediated apoptosis (Gardner and Johnson, 1996). Also, ERK activation has been implicated in FGF2-mediated angiogenesis in the chick chorioallantoic membrane (Eliceiri et al., 1998) whereas the antiangiogenic N-terminal fragment of prolactin prevents FGF2-mediated ERK phosphorylation in endothelial cells (D’Angelo et al., 1995). Nevertheless, ERK activation may not be sufficient to trigger a full biological response to FGF2 (Campbell et al., 1995; Bastaki et al., 1997; Dell’Era et al., 1999).

FGF2, Mr 18,000, is a single chain, nonglycosylated 155 amino acid protein (in the present paper the amino acid numbering 1-155 is used for full-length FGF2, even though amino acid numbering 1-146 can be encountered in the scientific literature, where the first residue corresponds to residue Pro-9). The three-dimensional structure of the 146-residue form of human FGF2 has been determined by X-ray crystallography (Zhu et al., 1990; Zhang et al., 1991; Eriksson et al., 1991; Faham et al., 1996). The heparin-binding domain of FGF2 is distinct from its FGFR-binding domain(s) and the formation of FGF2/HSPG/FGFR ternary complexes has been demonstrated (Guimond et al., 1993; Spivak-Krolzman et al., 1994; Rusnati et al., 1994). Thus, heparin interaction may affect the biological activity of FGF2 through different mechanisms including the modulation of its bioavailability, stabilization in the extracellular environment, intracellular fate and access to and dimerization of FGFRs (for a review, see Rusnati and Presta, 1996).

In order to investigate the structure/function relationship of the FGF2 molecule, variants have been developed by deletion or substitution of basic amino acid residues in the amino-terminal and carboxyl-terminal regions of FGF2 (Isacchi et al., 1991; Presta et al., 1992, 1993; Li et al., 1994). The neutralization of these basic residues caused a significant decrease in the urokinase-type plasminogen activator (uPA)-inducing activity of FGF2 without affecting its FGFR-binding capacity and mitogenic activity (Isacchi et al., 1991; Presta et al., 1992, 1993). These data are in keeping with the observation that the mitogenic activity and uPA-inducing capacity of FGF2 are mediated by different signal transduction pathways (Presta et al., 1989; Dell’Era et al., 1999) and that the interaction of FGF2 with FGFR is quantitatively and qualitatively different in mediating mitogenicity and uPA upregulation (Rusnati et al., 1996). Thus, FGF2 variants may represent useful tools to dissect the intracellular signaling activated by an angiogenic factor in endothelial cells.

In the present paper, we have investigated the capacity of wild-type FGF2 and FGF2 variants to cause ERK 1/2 phosphorylation, uPA upregulation and in vitro angiogenesis in bovine aortic endothelial (BAE) cells. The results demonstrate that ERK 1/2 activation is required for uPA upregulation and morphogenesis by FGF2. However, various FGF2 mutants showed a limited capacity to induce uPA activity and/or morphogenesis despite their ability to cause a sustained phosphorylation of ERK 1/2 in a manner indistinguishable from the wild-type molecule. These data demonstrate the possibility of dissociating FGF2-dependent ERK 1/2 activation from uPA upregulation and in vitro angiogenesis in endothelial cells by mutational analysis of the growth factor, and suggest that persistent ERK 1/2 phosphorylation is necessary but not sufficient for mediating these biological responses.

MATERIALS AND METHODS

Materials

Recombinant wild-type human FGF2 and FGF2 mutants were expressed in an Escherichia coli type B strain and purified by heparin-Sepharose affinity chromatography (Isacchi et al., 1991; Presta et al., 1992, 1993) with the only exception of recombinant R129Q/K134Q and K128Q/K138Q-FGF2 mutants (Li et al., 1994) that were a gift of A. Seddon (America Cyanamid Company, Pearl River, NY). The molecules were more than 95% pure, as evaluated by reverse-phase HPLC and SDS/PAGE analysis, and cross-reacted with polyclonal anti-FGF2 antibodies. Heparin was obtained from a commercial preparation of unfractionated sodium heparin from beef mucosa (batch 1131/900 from Laboratori Derivati Organici SpA, Milan, Italy). PD 098059, U0126 and SB 210313 were from Calbiochem (San Diego, CA), Promega (Madison, WI) and RBI (Natick, MA), respectively.

Cell cultures

Bovine aortic endothelial cells (provided by A. Vecchi, Istituto Mario Negri, Milan, Italy) were cultured in MEM-Eagle’s medium supplemented with 10% fetal calf serum (FCS), 2% essential amino acids and 2% vitamins. Cultures were used between the 6th and the 10th cell passage. CHO cells transfected with the murine FGFR1 cDNA (IIIc variant) were described previously (Rusnati et al., 1996).

125I-FGF2 cell binding

FGF2 was iodinated at 800 cpm/fmol as described (Neufeld and Gospodarowicz, 1985). BAE cells were incubated at 4°C in serum-free medium containing increasing concentrations of 125I-FGF2, 0.15% gelatin, 20 mM Hepes buffer (pH 7.5). After 2 hours, the amount of 125I-FGF2 bound to low- and high-affinity binding sites was evaluated as described (Moscatelli, 1987). Briefly, after a PBS wash, cells were rinsed twice with 2 M NaCl in 20 mM Hepes buffer (pH 7.5) to remove 125I-FGF2 bound to HSPGs, and twice with 2 M NaCl in 20 mM sodium acetate (pH 4.0) to remove 125I-FGF2 bound to FGRFs. Non-specific binding was measured in the presence of 150 μg/ml suramin and subtracted from all the values. Binding data were analyzed by Prism software (GraphPad Software, San Diego, CA).

Western blot analysis of ERK 1/2 phosphorylation

BAE cells were grown to subconfluence in 60 mm dishes. Then, cells were incubated for 30 minutes at 37°C with no addition or with PD 098059, U0126 or SB 210313 before addition of wild-type FGF2. At different times, western blot analysis of the cell extracts was performed as described (Besser et al., 1995) using anti-ERK2 antibodies (provided by Y. Nagamine, Friedrich Miescher Institute, Basel, Switzerland) or anti-phospho-ERK 1/2 antibody (New England
Biolabs, Inc., Beverly, MA). In some experiments, BAE cells were treated for different lengths of time with wild-type FGF2 or FGF2 mutant with or without 10 μg/ml heparin and ERK1/2 phosphorylation was evaluated as above. Also some cells were treated for 30 minutes with FGF2, added with PD 098059, or washed for 10 minutes with 100 μg/ml suramin (Gualandris and Presta, 1995), and assayed for ERK1/2 phosphorylation after 15 minutes.

**uPA upregulation assays**

Confluent cell cultures were incubated for 18-20 hours in fresh medium containing 0.4% FCS and increasing concentrations of wild-type FGF2 or of FGF2 mutant with or without 10 μg/ml heparin. When specified, cells were incubated for 30 minutes at 37°C with PD 098059, U0126 or SB 210313 before addition of the growth factor. After incubation, cell layers were washed twice with PBS and uPA activity was measured (by absorbance at 405 nm) in the cell extracts (Gualandris and Presta, 1995) by using the plasmin chromogenic substrate H-D-norleucyl-hexahydrotirosyl-lysine-p-nitroanilide-acetate (American Diagnostic, Greenwich, CT). Human uPA (60,000 U/mg of protein, Calbiochem) was used as a standard. Also, 20 μg samples of cell extracts were separated by 10% SDS-PAGE under non-reducing conditions. Then, zymography for the detection of uPA activity was carried out on a casein/agarose gel as described (Gualandris and Presta, 1995).

**Collagen gel assay**

For the preparation of three-dimensional gels of reconstituted collagen fibrils, 7 volumes of 1.5 mg/ml rat tail tendon type I collagen (Boehringer Mannheim Italia, Milan, Italy) dissolved in 0.1% acetic acid were mixed on ice with 2 volumes of 5x concentrated medium containing NaHCO₃ and 1 volume of 250 mM Hepes. The pH of the mixture was balanced by alkaline solution containing 1.0 M NaOH and 22 mg/ml NaHCO₃. The mixture was allowed to solidify in 24 well-plates (0.4 ml/well) at 37°C. Then, BAE cells were seeded on the top of collagen gel and allowed to reach confluence. Cell cultures were then treated with FGF2 or FGF2 mutants (10 ng/ml) with or without heparin (10 μg/ml) in the absence or in the presence of PD 098059 (20 μM), U0126 (10 μM) or SB 210313 (10 μM). All treatments were repeated 3 days later. At different times, cells were washed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4. The cultures were photographed under a phase-contrast microscope and then the gels were embedded in paraffin. Semithin sections (1 μm) were cut perpendicularly to the culture plane and stained with 1% Toluidine Blue. Experiments were performed in duplicate and repeated at least three times.

**RESULTS**

ERK1/2 activation is required for uPA upregulation and in vitro angiogenesis by FGF2 in BAE cells

Preliminary experiments were performed to characterize the interaction of FGF2 with BAE cells, ¹²⁵I-FGF2 binds to low-affinity HSPGs and high-affinity FGFRs (Moscatelli, 1987). Analysis of the binding data indicates that BAE cells express about 120,000 HSPG sites and 4,000 FGFRs per cell. Northern blot analysis on total RNA isolated from BAE cell cultures demonstrates that these cells express FGFR1 mRNA, whereas FGF2, FGFR3 and FGFR4 mRNA levels are below the limits of detection of the assay (data not shown).

FGF2 interaction with FGFR1 leads to activation of the Ras/Raf/MEK/ERK signaling pathway (Besser et al., 1995). Accordingly, FGF2 induces a rapid phosphorylation of ERK1/2 in BAE cells, detected as a mobility shift of ERK2 in SDS-PAGE and by western blot analysis with anti-phospho-ERK1/2 antibody (Fig. 1). A 30 minute preincubation of the cells with the MEK inhibitor PD 098059 (Alessi et al., 1995) completely prevents ERK1/2 phosphorylation induced by FGF2 (Fig. 1AB).

As shown in Fig. 2A, ERK1/2 phosphorylation is already maximal 30 minutes after treatment with FGF2, remains constant for the next 6 hours, and is still detectable at 14 hours. To assess whether the sustained phosphorylation of ERK1/2 requires a persistent stimulation by FGF2, cells were treated with FGF2 for 30 minutes to induce maximal phosphorylation of ERK1/2. Then, PD 098059 was added in the presence of FGF2, or the cells were washed with 100 μg/ml suramin to remove free and receptor-bound FGF2 (Gualandris and Presta, 1995). ERK1/2 phosphorylation was assessed 15 minutes thereafter. As shown in Fig. 2B, inhibition of MEK activity by PD 098059 or receptor-displacement of FGF2 by suramin cause a rapid (<15 minutes) dephosphorylation of ERK1/2. These data indicate that a transient stimulation of BAE cells by FGF2 is not sufficient to induce a long-lasting activation of ERK1/2, which depends upon a sustained stimulation of MEK activity consequent to a persistent FGF2-FGFR interaction.

To assess the role of ERK1/2 activation in FGF2-mediated uPA upregulation, BAE cells were incubated with FGF2 in the absence or in the presence of PD 098059. As shown in Fig. 3, PD 098059 prevents uPA upregulation by FGF2, as indicated by cell-associated uPA activity assay and SDS-PAGE zymography. In contrast, SB 210313, a selective inhibitor (Cuenda et al., 1995) of the ERK1/2-related mitogen-activated protein kinase p38 (Lin et al., 1995), had no effect on ERK1/2 phosphorylation (Fig. 1) and uPA upregulation (Fig. 3).

The capacity of endothelial cells to form capillary-like structures within three-dimensional matrices has been used widely as an in vitro model of angiogenesis (Montesano et al., 1986; Kubota et al., 1988; Gualandris et al., 1996).
Accordingly, confluent BAE cell cultures seeded on a threedimensional type I collagen gel form numerous hollow capillary-like structures beneath the gel surface when treated with FGF2 (see Fig. 4 and Fig. 8C,F). Furthermore, under these conditions, PD 098059 treatment abolished the morphogenic activity of FGF2 whereas SB 210313 was ineffective (Fig. 4).

Taken together, the data indicate that FGF2/FGFR1 interaction leads to a sustained, MEK-dependent ERK1/2 phosphorylation in BAE cells. Activation of this signaling pathway is required to transduce uPA upregulation and morphogenesis by FGF2.

**ERK1/2 activation and uPA upregulation by FGF2 mutants**

Wild-type FGF2 and FGF2 mutants (their schematic structures are shown in Fig. 5) were compared for their capacity to induce ERK1/2 activation in BAE cells. All FGF2 mutants cause the rapid phosphorylation of ERK1/2, detected as a mobility shift of ERK2 (Fig. 6A), and by western blot analysis with anti-phospho-ERK1/2 antibody (Fig. 6B). For all mutants, ERK1/2 phosphorylation occurs both in the absence and in the presence of soluble heparin (10 µg/ml) in the culture medium. Also, no significant differences were observed in the kinetics of ERK1/2 phosphorylation between wild-type FGF2 and mutant R118,129Q/K119,128Q-FGF2 during the first 24 hours of stimulation (Fig. 6C). Similar results were obtained when the two molecules were tested in the presence of free heparin (data not shown).

In contrast, when the FGF2 mutants were evaluated for their uPA-inducing capacity (Fig. 7A), only R129Q/K134Q-FGF2 and K128Q/R129Q-FGF2 were able to upregulate cell-associated uPA activity in BAE cells in a manner similar to R118,129Q/K119,128Q-FGF2 during the first 24 hours of stimulation (Fig. 6C). Similar results were obtained when the two molecules were tested in the presence of free heparin (data not shown).

In contrast, when the FGF2 mutants were evaluated for their uPA-inducing capacity (Fig. 7A), only R129Q/K134Q-FGF2 and K128Q/R129Q-FGF2 were able to upregulate cell-associated uPA activity in BAE cells in a manner similar to

---

**Fig. 2.** Kinetics of ERK1/2 phosphorylation induced by FGF2. (A) BAE cells were treated with 30 ng/ml FGF2. At the indicated times, cell extracts were probed using anti-phospho-ERK1/2 antibodies. (B) BAE cells were incubated without (control) or with 30 ng/ml FGF2 for 30 minutes (FGF2). Then, 20 µM PD 098059 were added to half of the FGF2-treated cell cultures without changing the medium (FGF2+PD 098059) and the other half were washed for 10 minutes at room temperature with 100 µg/ml suramin and then added to fresh medium without FGF2 (FGF2+suramin). Western blot analysis of the cell extracts was performed 15 minutes thereafter using anti-phospho-ERK1/2 antibodies. *ERK1/2, phosphorylated ERK.

**Fig. 3.** uPA upregulation by FGF2 requires ERK1/2 activation. BAE cells were incubated for 18-20 hours without (control) or with 30 ng/ml FGF2 in the absence (FGF2) or in the presence of 20 µM PD 098059 (FGF2+PD) or SB 210313 (FGF2+SB). uPA activity was then measured by absorbance at 405 nm in the cell extracts, utilizing a chromogenic plasmin substratum. Data are expressed as mean ± s.d. **Significantly different from the control, P<0.01. (n=5). (Inset) SDS-PAGE zymography of BAE cell extracts. (a) Control; (b) FGF2 alone; (c) FGF2+PD 098059; (d) FGF2+SB 210313.

**Fig. 4.** Angiogenesis in vitro by FGF2 requires ERK1/2 activation. BAE cells grown to confluence on type I collagen gel were treated with FGF2 (30 ng/ml) in the absence or in the presence of 20 µM PD 098059 or 10 µM SB 210313. At day 3, cells were fixed and photographed under a phase-contrast microscope. (A) Control; (B) +FGF2; (C) FGF2+PD 098059; (D) FGF2+SB 210313. In B and D, the plane of focus is beneath the cell surface.
Table 1. Morphogenic activity of FGF2 mutants in BAE cells

<table>
<thead>
<tr>
<th>Capillary-like tube formation</th>
<th>Morphological phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-heparin</td>
</tr>
<tr>
<td>Control</td>
<td>–</td>
</tr>
<tr>
<td>FGF2</td>
<td>++</td>
</tr>
<tr>
<td>$\Delta_{27-32}$-FGF2</td>
<td>–</td>
</tr>
<tr>
<td>K$<em>{27,30}$Q/R$</em>{31}$Q-FGF2</td>
<td>–</td>
</tr>
<tr>
<td>K$<em>{128}$Q/R$</em>{129}$Q-FGF2</td>
<td>Rare</td>
</tr>
<tr>
<td>R$<em>{118,129}$Q/K$</em>{119,123}$Q-FGF2</td>
<td>Rare</td>
</tr>
<tr>
<td>R$<em>{129}$Q/K$</em>{134}$Q-FGF2</td>
<td>Rare</td>
</tr>
<tr>
<td>K$<em>{128}$Q/K$</em>{138}$Q-FGF2</td>
<td>–</td>
</tr>
</tbody>
</table>

Wild-type FGF2 or FGF2 mutants were added at 10 ng/ml to BAE cell cultures seeded onto three-dimensional type I collagen gel in the absence or in the presence of 10 μg/ml heparin. All treatments were repeated 3 days later. At day 6, cells were evaluated for the formation of tubular structures.

Morphological phenotypes: a, quiescent monolayer (see Fig. 4A,D); b, activated monolayer (see Fig. 4B,E); c, invasive phenotype (see Fig. 4C,F); b/c, activated monolayer with rare tubular structures.

Taken together, these data demonstrate that various FGF2 mutants have lost the ability to induce uPA upregulation despite their capacity to cause long-lasting ERK$_{1/2}$ activation.

In vitro angiogenesis by FGF2 mutants

When confluent BAE cell cultures were seeded on collagen gel and treated with wild-type FGF2 or FGF2 mutants for 6 days, three highly reproducible morphological phenotypes were observed under the various experimental conditions: (1) the maintenance of a quiescent cobblestone monolayer; (2) the appearance of an activated monolayer characterized by non-invasive, elongated, swirling cells; (3) the induction of an invasive phenotype characterized by the formation of numerous hollow capillary-like structures beneath the gel surface. An intermediate phenotype characterized by an activated monolayer with rare capillary-like structures was also observed under some experimental conditions (see below). The three main phenotypes are shown in Fig. 8, as they appear when the intact gel is observed under a phase-contrast microscope or when semi-thin sections perpendicular to the culture plane are analysed.

As summarized in Table 1, BAE cells grown on collagen gel form tube-like structures in response to wild-type FGF2 (phenotype ‘c’). In contrast, the maintenance of a regular cobblestone monolayer is observed for untreated cells or for cells treated with $\Delta_{27-32}$-FGF2, R$_{118,129}$Q/K$_{119,123}$Q-FGF2 or K$_{128}$Q/K$_{138}$Q-FGF2 (phenotype ‘a’). K$_{27,30}$Q/R$_{31}$Q-FGF2 induced instead the formation of an activated monolayer devoid of capillary-like structures (phenotype ‘b’), which were present only in very low numbers in cell cultures treated with K$_{128}$Q/R$_{129}$Q-FGF2 or R$_{129}$Q/K$_{134}$Q-FGF2 (intermediate phenotype ‘b/c’). Heparin potentiates to a varying extent the morphogenic activity of FGF2 mutants with the exception of $\Delta_{27-32}$-FGF2, which remained inactive, and R$_{129}$Q/K$_{134}$Q-FGF2, which induced the appearance of an intermediate phenotype ‘b/c’ even in the presence of heparin (Table 1). Thus, the various FGF2 mutants exert a different morphogenic

![Fig. 5. Schematic representation of the FGF2 mutants utilized in the present study. Mutagenized regions are in boxes and residues are shown in single letter code. Δ, deletion.](image-url)
activity on BAE cells, which is restored, at least in part, by soluble heparin.

**Effect of MEK inhibitor U0126 on ERK$_{1/2}$ activation, uPA upregulation and morphogenesis**

To assess whether the morphogenic capacity and uPA-inducing activity retained by some of the FGF2 mutants tested were still dependent on ERK$_{1/2}$ activation, R$_{118,129}$Q/K$_{119,128}$Q-FGF2 plus heparin or wild-type FGF2 were added to BAE cells in the absence or in the presence of the novel MEK inhibitor U0126 (Favata et al., 1998). As shown in Fig. 9, U0126 fully prevents ERK$_{1/2}$ activation, uPA upregulation and morphogenesis induced by wild-type FGF2 and R$_{118,129}$Q/K$_{119,128}$Q-FGF2 plus heparin. Identical results were obtained with PD 098059 (data not shown). Again, p38 inhibitor SB 210313 was ineffective (Fig. 9).

**DISCUSSION**

In the present paper we demonstrate that FGF2/FGFR1 interaction induces a persistent ERK$_{1/2}$ phosphorylation in BAE cells and that the MEK inhibitors PD 098059 and U0126 prevent ERK$_{1/2}$ phosphorylation as well as uPA upregulation and in vitro angiogenesis in FGF2-treated cells. The two inhibitors hamper MEK activity in different ways. PD 098059 prevents the Raf-dependent phosphorylation of the enzyme, whereas U0126 blocks the catalytic activity of activated MEK (Favata et al., 1998). This fact, together with the inability of the protein kinase p38 inhibitor SB 210313 to affect FGF2 activity, strongly indicates that ERK$_{1/2}$ activation by MEK is an essential step in the signal transduction pathway(s) leading to uPA induction and morphogenesis by FGF2 in cultured endothelial cells. Previous observations had implicated ERK activation in FGF signaling (Pages et al., 1993; Milasincic et al., 1996; Besser et al., 1995) and in FGF2-mediated angiogenesis in the chick chorioallantoic membrane (Eliceiri et al., 1998). Interestingly, the antiangiogenic N-terminal fragment of prolactin prevents FGF2-induced ERK phosphorylation in endothelial cells (D’Angelo et al., 1995). Our results emphasize the role of ERK$_{1/2}$ in signal transduction activated by FGFR1 occupancy in endothelium. Nevertheless, we have also observed that different FGF2 mutants derived by neutralization of basic residues located either in the amino-terminal region or in the carboxyl-terminal region of the molecule are characterized by a reduced uPA-inducing activity and/or morphogenic capacity, despite their ability to activate ERK$_{1/2}$ in a manner indistinguishable from the wild-type growth factor. Thus, our data indicate that ERK$_{1/2}$ phosphorylation following FGF2/FGFR1 interaction is necessary but not sufficient for triggering a full biological response in endothelial cells.

These findings are in keeping with the inability of wild-type FGF2 to upregulate uPA activity and to induce fibrin gel invasion in murine aortic endothelial cell cultures even though they respond to the growth factor with a rapid activation of ERK$_{1/2}$ and $^3$H-thymidine incorporation (Bastaki et al., 1997). Interestingly, the role of ERK activation in FGF2-dependent inhibition of myoblast differentiation has been questioned (discussed in Milasincic et al., 1996). Also, activation of the MEK/ERK cascade plays an important role in insulin-stimulated c-fos induction and mitogenicity but it is not sufficient to induce insulin-dependent metabolic effects such as upregulation of glycogen synthase activity and glucose transport (Denton and Tavaré, 1995).

Previous observations on different cell types have indicated that the duration of ERK$_{1/2}$ phosphorylation dictates the biological consequences of the activation of this signaling pathway.
pathway. For instance, epidermal growth factor and nerve growth factor bind different tyrosine-kinase receptors in PC12 cells but their intracellular signaling converges to ERK1/2 activation. However, nerve growth factor causes a sustained activation of ERK1/2 that leads to cell differentiation, whereas the transient ERK1/2 activation induced by epidermal growth factor triggers a proliferative signal (for a comprehensive discussion on this point, see Marshall, 1995). Here we have observed that wild-type FGF2 and various FGF2 mutants induce a persistent activation of ERK1/2 in endothelial cells. Depending upon the FGF2 mutant tested, this leads to endothelial cell proliferation, protease production and/or morphogenesis, suggesting that factors other than the kinetics of ERK1/2 activation dictate the complex response of endothelial cells to an angiogenic stimulus. Interestingly, recent observations have shown that survival and
The morphogenesis of human umbilical vein endothelial cells in 3-D collagen gel are modulated by multiple signal transduction pathways, including ERK1/2, phosphoinositide 3-OH kinase and Akt pathways (Ilan et al., 1998). However, we were unable to demonstrate activation of phosphoinositide 3-OH kinase and Akt pathways by FGF2 in BAE cells (R. Giuliani and M. Presta, unpublished observations).

A previous characterization of the biological activity of the FGF2 mutants utilized in the present study indicated that Δ27-32-FGF2, K27,30Q/R31Q-FGF2 and R118,129Q/K119,128Q-FGF2 plus 10 μg/ml heparin. After 20 minutes, western blot analysis of the cell extracts was performed using anti-phospho-ERK1/2 antibodies. *ERK1/2: phosphorylated ERK. (B) Cells were incubated for 30 minutes at 37°C with no addition (open bars), 20 μM SB 210313 (striped bars) or 10 μM U0126 (black bars), before addition of 30 ng/ml FGF2 or R118,129Q/K119,128Q-FGF2 plus 10 μg/ml heparin. After 18-20 hours of incubation at 37°C, uPA activity was measured (by absorbance at 405 nm) in the cell extracts utilizing a chromogenic plasmin substratum. Data are expressed as mean ± s.d. **Significantly different from untreated cells (dashed line), P<0.01. (C) BAE cells grown at confluence on type I collagen gel were treated with 30 ng/ml FGF2 (a,c) or R118,129Q/K119,128Q-FGF2 plus 10 μg/ml heparin (b,d) in the absence (a,b) or in the presence (c,d) of 10 μM U0126. At day 2-3, cells were fixed and photographed under a phase-contrast microscope. The plane of focus is beneath the cell surface.

Fig. 9. ERK inhibitor U0126 prevents ERK1/2 activation, uPA upregulation and morphogenesis in BAE cells.

(A) Cells were incubated for 30 minutes at 37°C with no addition, 20 μM SB 210313 (+SB), or 10 μM U0126 (+U) before addition of 30 ng/ml FGF2 or R118,129Q/K119,128Q-FGF2 plus 10 μg/ml heparin. After 20 minutes, western blot analysis of the cell extracts was performed using anti-phospho-ERK1/2 antibodies. *ERK1/2: phosphorylated ERK. (B) Cells were incubated for 30 minutes at 37°C with no addition (open bars), 20 μM SB 210313 (striped bars) or 10 μM U0126 (black bars), before addition of 30 ng/ml FGF2 or R118,129Q/K119,128Q-FGF2 plus 10 μg/ml heparin. After 18-20 hours of incubation at 37°C, uPA activity was measured (by absorbance at 405 nm) in the cell extracts utilizing a chromogenic plasmin substratum. Data are expressed as mean ± s.d. **Significantly different from untreated cells (dashed line), P<0.01. (C) BAE cells grown at confluence on type I collagen gel were treated with 30 ng/ml FGF2 (a,c) or R118,129Q/K119,128Q-FGF2 plus 10 μg/ml heparin (b,d) in the absence (a,b) or in the presence (c,d) of 10 μM U0126. At day 2-3, cells were fixed and photographed under a phase-contrast microscope. The plane of focus is beneath the cell surface.
sustained phosphorylation of ERK1/2 and cell proliferation, but to allow a persistent interaction with FGFR1 that triggers a Presta et al., 1992, 1993) but are devoid of a significant uPA-endowed with a full mitogenic activity (Isacchi et al., 1991; partial activation of FGFR1 sufficient to stimulate long-lasting interactions of peptide hormones with their cell membrane receptors and consequent activation of one or more intracellular signaling pathways. On this basis, it seems possible to hypothesize that the FGF2 mutants utilized in the present study may interact differently with FGFR1 and that this interaction, markedly affected by soluble heparin, leads to a partial activation of FGFR1 sufficient to stimulate long-lasting ERK1/2 activation and cell growth but not to trigger uPA upregulation and morphogenesis. Further studies on the signaling transduction pathway(s) responsible for the different biological effects exerted by FGF2 in endothelial cells are required to elucidate this point. Site-directed mutagenesis of the FGF2 molecule may represent an useful tool for dissecting the complex response elicited by FGF2 in endothelial cells during angiogenesis.

This work was supported in part by Associazione Italiana per la Ricerca sul Cancro, University of Brescia (Centro per lo Studio del Trattamento dello Scompenso Cardiaco), Ministero Superiore della Sanità (AIDS Project), Ministero Università Ricerca Scientifica e Tecnologica (Cofinanziamento 1997: Project ‘Inflammation: Biology and Clinics’ and ‘60%’), Consiglio Nazionale Ricerche (Target Project Biotechnology no. 97.01186.PF49) to M.P. and by European Community (Human Capital Mobility Project ‘Mechanisms for the Regulation of Angiogenesis’) to M.P. and M.B.

REFERENCES


Gualandris, A., Rusnati, M., Belleri, M., Nelli, E. E., Bastaki, M., Molinari-Tosatti, M. P., Bonardi, E., Parolini, S., Albini, A., Morbidelli,


